100 related articles for article (PubMed ID: 15253989)
1. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Townsend M; MacIver DH
Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
[TBL] [Abstract][Full Text] [Related]
2. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Ling LH; Ahlskog JE; Munger TM; Limper AH; Oh JK
Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
[TBL] [Abstract][Full Text] [Related]
3. [Constrictive pericarditis caused by carbergoline].
Hjortshøj SP; Poulsen SH; Andreasen JJ
Ugeskr Laeger; 2006 Jun; 168(26-32):2572-3. PubMed ID: 16824416
[TBL] [Abstract][Full Text] [Related]
4. A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Löndahl M; Nilsson A; Lindgren H; Katzman P
Eur J Endocrinol; 2008 Apr; 158(4):583-5. PubMed ID: 18362307
[TBL] [Abstract][Full Text] [Related]
5. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
[No Abstract] [Full Text] [Related]
6. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases.
Champagne S; Coste E; Peyrière H; Nigond J; Mania E; Pons M; Hillaire-Buys D; Balmes P; Blayac JP; Davy JM
Ann Pharmacother; 1999 Oct; 33(10):1050-4. PubMed ID: 10534217
[TBL] [Abstract][Full Text] [Related]
7. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
Sato T; Kikuchi A; Onoue N; Hiramoto T; Oumi M; Onodera J
Rinsho Shinkeigaku; 2008 Jul; 48(7):486-91. PubMed ID: 18717182
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.
Dhawan V; Medcalf P; Stegie F; Jackson G; Basu S; Luce P; Odin P; Chaudhuri KR
J Neural Transm (Vienna); 2005 May; 112(5):661-8. PubMed ID: 15785862
[TBL] [Abstract][Full Text] [Related]
9. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
Haro-Estarriol M; Sabater-Talaverano G; Rodríguez-Jerez F; Obrador-Lagares A; Genís-Batlle D; Sendra-Salillas S
Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272
[TBL] [Abstract][Full Text] [Related]
10. [Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment].
Saura J; Aguilar M; Alió J
Neurologia; 1991 Nov; 6(9):331-3. PubMed ID: 1809340
[TBL] [Abstract][Full Text] [Related]
11. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Frans E; Dom R; Demedts M
Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
[TBL] [Abstract][Full Text] [Related]
12. Pleural fibrosis associated with dihydroergocryptine treatment.
Oechsner M; Groenke L; Mueller D
Acta Neurol Scand; 2000 Apr; 101(4):283-5. PubMed ID: 10770528
[TBL] [Abstract][Full Text] [Related]
13. Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide.
Balachandran KP; Stewart D; Berg GA; Oldroyd KG
Postgrad Med J; 2002 Jan; 78(915):49-50. PubMed ID: 11796875
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
[TBL] [Abstract][Full Text] [Related]
15. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
16. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Tintner R; Manian P; Gauthier P; Jankovic J
Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
[TBL] [Abstract][Full Text] [Related]
17. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
Todman DH; Oliver WA; Edwards RL
Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961
[TBL] [Abstract][Full Text] [Related]
18. [Pleuropulmonary fibrosis and bromocriptine].
Vergeret J; Barat M; Taytard A; Bellvert P; Domblides P; Douvier JJ; Fréour P
Sem Hop; 1984 Mar; 60(11):741-4. PubMed ID: 6324351
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline in Parkinson's disease complicated by motor fluctuations.
Geminiani G; Fetoni V; Genitrini S; Giovannini P; Tamma F; Caraceni T
Mov Disord; 1996 Sep; 11(5):495-500. PubMed ID: 8866490
[TBL] [Abstract][Full Text] [Related]
20. Mitral heart disease due to cabergoline.
Martin M; Iglesias-Cubero G; Diaz Molina B; Moris De la Tassa C
Int J Cardiol; 2007 Jan; 114(1):e7-8. PubMed ID: 17052783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
